



Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2132.030

APPLICATION NO.
09/845,715

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
JACKOWSKI et al.

FILING DATE
04/30/01

GROUP
1631

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	INVENTION IF APPROPRIATE
COL AS	5,538,897	07/96	Yates, III et al.	436	89 RECEIVED DEC 11 2002
					TECH CENTER 1600/2900
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	TRANSLATION
COL AS	WO 87/06344	10/87	PCT		X
COL	WO 91/13352	09/91	PCT		X
COL	WO 98/23290	07/98	PCT		X
	WO 01/05422	01/01	PCT		X
COL AS	WO 00/49410	08/00	PCT		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

COL AS	Tang, et al., "Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans", Journal of Immunology (1999), Vol. 162, No. 7, pp. 4336-4341.
COL	Koch, et al., "A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody", Immunogenetics (1986), Vol. 23, No. 5, pp. 322-325.
COL	Beaudry, et al., "Complement C3 (C3F) As a Risk Factor for Stroke", Stroke (1990), Vol. 21, No. 1, p.168.
COL	Muscat, et al., "Association of Serum C3 Levels With the Risk of Myocardial Infarction", American Journal of Medicine (1995), Vol. 98, No. 4, pp. 357-364.
COL	Harrison et al., "Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement", Component (1988), Vol. 5, No. 1, pp. 27-32.
COL	Agarwal, et al., "Immunologic Parameters in Infective Endocarditis: A Prospective Study", Indian Heart Journal (1991-05), Vol. 43, No. 3, pp. 179-183.
COL	Kristensen, et al., "Association Between Coronary Heart Disease and the C3F-Gene in Essential Hypertension", Circulation (1978), Vol. 58, No. 4, pp. 622-625.

EXAMINER

DATE CONSIDERED

2/25/03 // 12/16/2005

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Rev. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION FEB 11 2002 (Use several sheets if necessary)								Atty. Docket No. 2132.030	Serial No. 09/845,715			
								Applicant Jackowski et al.				
								Filing Date 04/30/01	Group 1631 1645			
RECEIVED FEB 15 2002 TECH CENTER 1600/2000												
U. S. PATENT DOCUMENTS												
Examiner Initial		DOCUMENT NUMBER						Date	Name	Class	Subclass	Filing Date if Appropriate
CRW		6	0	2	0	2	0	8	02/01/00	Hutchens et al	436	174
CRW		5	0	6	2	9	3	5	11/05/91	Schlag et al	204	157.4
FOREIGN PATENT DOCUMENTS												
		Document Number				Date	Country	Class	Subclass	Translation Yes No		
CRW		WO 98/07036				02/19/98	PCT			X		
CRW		WO 90/14148				11/29/90	PCT					
CRW		WO 93/24834				12/09/93	PCT					
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>												
CRW		Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.										
CRW		Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.										
EXAMINER		<i>CRW</i>							DATE CONSIDERED	<i>12/16/2005</i> <i>2/25/03</i>		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.